Despite advancements in treatment, multiple myeloma (MM) remains without a cure and nearly always develops refractoriness to the 3 primary classes of standard therapies (immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal antibodies (αCD38 mAbs). The gene discussed is CD38; the disease is plasma cell myeloma.